Sort by topic:

AxSpa Treatment Goals and Windows of Opportunity


Hillary Norton, MD, considers the windows of opportunity in managing axial spondyloarthritis to prevent various comorbidities and discusses the goals of therapy. 

Transcript

Hillary Norton, MD: The goals of therapy are to minimize the symptoms, to maintain function, to minimize extra-articular complications, and to minimize complications of spinal disease.
The goals of therapy do vary from patient to patient and are very personal. Many patients are athletes and want to continue to perform at a high level. Other patients have different personal goals, but maintenance of function and decrease in pain are shared goals among all patients.

The ASDAS [ankylosing spondylitis disease activity score] is a composite disease severity index that is used primarily in clinical trials to assess disease activity. And it looks at factors such as back pain, stiffness, and patient global and inflammatory markers such as ESR [erythrocyte sedimentation rate] and CRP [C-reactive protein].

The ASDAS measure is primarily used for research. In the clinic, we have some other outcome measures that may be used, such as the BASDAI [Bath ankylosing spondylitis disease activity index], which can assess disease severity so that we can assess how a patient is doing.

Early diagnosis of axSpA is very important primarily for quality of life for the patient. This prevents unnecessary medical costs and unnecessary invasive procedures if a correct diagnosis is made. Additionally, we can treat the root of the disease instead of just treating the pain.

An active area of research right now is whether nonradiographic axSpA will always progress to AS [ankylosing spondylitis]. And this is still unknown. We do think that early treatment of nonradiographic axSpA may prevent many of the complications of disease, and we are increasingly getting data that tell us that this may prevent nonradiographic disease from progressing. But the answers to this are not entirely known yet.

There are factors that can increase the risk of progression from nonradiographic disease to AS, including early syndesmophytes seen in the spine as well as male gender.
 


Episode #1

Axial Spondyloarthritis Defined
Axial Spondyloarthritis Defined

Episode #2

Epidemiology of Axial Spondyloarthritis
Epidemiology of Axial Spondyloarthritis

Episode #3

Accurately Diagnosing Axial Spondyloarthritis
Accurately Diagnosing Axial Spondyloarthritis

Episode #4

Unmet Needs in the Diagnosis of Axial Spondyloarthritis
Unmet Needs in the Diagnosis of Axial Spondyloarthritis

Episode #5

Axial Spondyloarthritis and Quality of Life
Axial Spondyloarthritis and Quality of Life

Episode #6

Establishing Goals of Therapy in Axial Spondyloarthritis
Establishing Goals of Therapy in Axial Spondyloarthritis

Episode #7

Clinical Recommendations: Managing Axial Spondyloarthritis
Clinical Recommendations: Managing Axial Spondyloarthritis

Episode #8

Treating Axial Spondyloarthritis
Treating Axial Spondyloarthritis

Episode #9

Axial Spondyloarthritis: Future Outlook
Axial Spondyloarthritis: Future Outlook

Episode #10

Nonradiographic Versus Radiographic Axial Spondyloarthritis
Nonradiographic Versus Radiographic Axial Spondyloarthritis

Episode #11

The Epidemiology of Axial Spondyloarthritis
The Epidemiology of Axial Spondyloarthritis

Episode #12

Diagnosing Axial Spondyloarthritis
Diagnosing Axial Spondyloarthritis

Episode #13

AxSpa Treatment Goals and Windows of Opportunity
AxSpa Treatment Goals and Windows of Opportunity
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$